The size of the Latin America RNAi Drug Delivery Market had a market value of USD 8.93 billion in 2022 and is forecasted to exhibit a CAGR of 26% and reach USD 28.37 billion by 2027.
The increasing prevalence of chronic diseases, such as cardiac abnormalities, cancer, and other genetic disorders, drives the RNAi drug delivery market. The growing geriatric population is more prone to various chronic diseases, significantly influencing the demand for the RNAi drug delivery market in this region. In addition, RNAi plays a significant role in the development of therapeutic gene silencing. The rapid increase in the application in therapeutics, agriculture, drug delivery, and research and development are expanding the market growth.
Medical research institutions are also developing RNA medicines regularly. By increasing stability, academic research and activities also encourage the usage of novel drug delivery technologies and pharmacological enhancements. Furthermore, the recent global pandemic COVID-19 rapidly increased the demand for RNAi drug delivery technologies. The major companies in the region are engaged in the adoption of advanced RNA therapeutics. The increased research activities in the field of nanotechnology are expected to provide lucrative growth opportunities to the market growth.
Increasing investments by the government and non-government organizations to develop healthcare infrastructure, research and development activities, and medical tourism across the region are boosting the market growth. Furthermore, the market strategies implemented by the key market players in the region are strengthening the regional market growth. The strategies include mergers, collaborations, and acquisitions between life sciences companies. In addition, government authorities in Latin America's emerging countries are taking steps to provide improved medication delivery to all population segments to improve health care services, driving the RNAi drug delivery market forward.
However, the lack of proper distribution of networks of RNAi drug delivery, the absence of skilled professionals in drug control laboratories, and stringent government regulations are impeding the RNAi market in the region. In addition, the risk of failure and the poor healthcare infrastructure in some of the countries in the region are restricting the market growth.
This research report on the Latin America RNAi Drug Delivery market has been segmented and sub-segmented into the following categories.
By Drug Delivery:
By Therapeutic Application:
By Country:
Globally, the Latina American market is anticipated to grow at a prominent pace during the forecast period. In Latin America, most of the market share is contributed by the emerging countries in the region, such as Brazil, Argentina, and Mexico. Scientists are currently working to identify the genes that cause cancer and develop an RNAi drug to combat them, as this trend has been significantly evolving in recent years. Moreover, the emerging economies are attempting to enhance medicine distribution to all segments of the population to improve health care services, propelling the RNAi drug delivery market further.
Brazil accounts for the largest share of the RNAi market owing to the country's improved life science research infrastructures. Also, the increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases, is significantly fuelling the market growth.
On the other hand, emerging countries such as Argentina and Mexico are projected to register a moderate share in the region. Technological advancements in the healthcare sector, increasing geriatric population, and supportive government policies.
KEY MARKET PLAYERS:
Companies that dominate the Latin American RNAi drug delivery market profiled in this report are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region